Clinical trial starts in June, involves some 30 TTSH patients like stroke survivors Neural Drive co-founder Khambhati Mohammed Huzefa revealing…
Read More
Do All Patients in Europe Have Equal Acess to Cancer Clinical Trials? – ESMO
European Society for Medical Oncology (ESMO), shared a post on LinkedIn: “Do all patients in Europe have equal access to…
Read More
Kaiser nurses protest Bay Area layoffs, fearing patients will suffer
Kaiser Permanente nurses in the Bay Area are rallying against impfinishing layoffs, declareing the job cuts to an already stretched-thin…
Read More
Do patients have a right to understand health AI? • healthcare-in-europe.com
Anshu Ankolekar, PhD., JMIR Correspondent Image credit: Anshu Ankolekar The article, “The Right to Understand in Health Care AI,” explores…
Read More
How Indian American Founders of Latent Health Are Using AI to Get Life-Saving Medications to Patients Faster
Rishabh Jain and Sriram Somasundaram, co-founders of Latent Health, have built a $600 million AI startup that is tackling one…
Read More
Cancer Patients Europe Pushes for EU Action on Inequalities – CancerWorld
CancerWorld, shared a post on LinkedIn: “Across Europe, cancer outcomes still depconclude on geography. That must modify. Cancer Patients Europe…
Read More
The European Commission extconcludeed the Marketing Authorisation for Vueway® (gadopiclenol) in the European Union for utilize in pediatric patients under 2 years of age
Expanded EU approval reflects positive benefit-risk ratio of Vueway® in children from birth – Advertisement – MILAN, Jan. 27, 2026…
Read More
This doctor noticed kids fear dentists & built India’s first sensory pediatric dental clinic, has treated 45k+ patients with 20% YoY growth
In India, pediatric dentistest (that is, dentistest for children) has not gained much prominence, and it has not been taken…
Read More
More than 500 New Jersey Optum employees laid off, notified by video email as patients fear what’s next
Thousands of patients across the state will have to find new doctors or specialists after Optum announced it is laying…
Read MoreRaludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the…
Read More
